InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
0.00%
)
US TECH 100
19,164.40
(
-0.22%
)
Dow Jones
39,150.33
(
0.00%
)
Brent Oil
84.59
(
0.67%
)
Bitcoin
61,205.44
(
-3.09%
)
Post# of 252314
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 123710

Thursday, 01/19/2012 7:27:49 AM

Thursday, January 19, 2012 7:27:49 AM

Post# of 252314
NVS starts phase-3 trials for Neupogen/Neulasta FoB’s:

http://www.novartis.com/newsroom/media-releases/en/2012/1578463.shtml

These programs seek FDA regulatory approval via the traditional BLA pathway, not the new 351(k) pathway, which implies that they will be non-substitutable for the corresponding branded products from AMGN.

Teva is also a player in the market for Neopogen/Neulasta FoB’s, and it reached a partial patent settlement with AMGN (#msg-65841959, #msg-65308970).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up